HYDERABAD, India / Jan 23, 2025 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS).

Commenting on the results, Co-Chairman & MD, G V Prasad said: “We delivered double digit growth aided by our newly acquired NRT business, new launches and improved operational efficiencies. We remain committed to addressing patient needs by advancing healthcare through access, affordability and innovation.”

All amounts in millions, except EPS All US dollar amounts based on convenience translation rate of 1 USD = ₹85.55

Dr. Reddy’s Laboratories Limited & Subsidiaries

Revenue Mix by Segment for nine months

Key Business Highlights [for Q3FY25]

• Consolidated Nicotine Replacement Therapy (‘NRT’) financials in this quarter. Integration of the NRT business progressing as per plan.
• Entered into a voluntary licensing agreement with Gilead Sciences to manufacture and commercialise HIV treatment drug, Lenacapavir, in 120+ countries.
• Promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma announced by our subsidiary, Aurigene Oncology Limited.
• Denosumab biosimilar filing completed for the US and Europe by our partner, Alvotech.
• Launched Toripalimab, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma in India.
• Launched Elobixibat, a first-in-class drug to treat chronic constipation, under the brand name BixiBat^®, in India.

ESG Highlights [for Q3FY25]

• MSCI ESG rating upgraded to ‘A’ in December 2024.
• Placed 5th globally amongst pharma companies assessed in the 2024 S&P Global’s Corporate Sustainability Assessment, with an ESG score of 79/100.
• Continue to be members of the DJSI World Index for the 2^nd year in a row, along with the DJSI Emerging Markets Index for the 9^th year in a row.
• Continue to feature amongst NIFTY 100 ESG Sector Leaders.
• Named in TIME & Statista's global list of ‘World's Best Companies - Sustainable Growth’
• Named in Science Magazine’s ‘Top 20 global pharma and biotech employers’ for the 3^rd consecutive year.

Other Updates [for Q3FY25]

• Good Manufacturing Practice (GMP) inspection completed by the USFDA at our API facility, CTO-2, in Bollaram, Hyderabad in November, 2024 and issued a Form 483 with seven observations. The response to the observations were submitted within stipulated timelines.
• Completed alteration in share capital of the Company by sub-division/ split of existing equity shares of face value of ₹5 each, fully paid up, into 5 equity shares of ₹1 each, fully paid-up. Further, each American Depositary Share (ADS) continues to represent one underlying equity share and, therefore, the number of ADSs held by an American Depositary Receipt (ADR) holder has increased proportionately.

Revenue Analysis

• Q3FY25 consolidated revenues at ₹83.6 billion, YoY growth of 16% and sequential growth of 4%. Underlying YoY growth excluding NRT is 7.5% and a decline of 3% QoQ.
  
  9MFY25 consolidated revenues at ₹240.5 billion, YoY growth of 15%. Underlying YoY growth excluding NRT is 12.5%.
  
  The growth was largely driven by revenues from the recently acquired Nicotine Replacement Therapy (NRT) portfolio, revenues from India and Emerging Markets.

Global Generics (GG)

• Q3FY25 revenues at ₹73.8 billion, YoY growth of 17% and QoQ growth of 3%. Underlying growth excluding NRT is 7% YoY and a decline of 5% QoQ.
  
  9MFY25 revenues at ₹214.2 billion, a YoY growth of 16%. Underlying YoY growth excluding NRT is 13% for 9MFY25.
  
  Growth was largely driven by revenues from the acquired NRT portfolio, higher volumes and new product launches.

North America

• Q3FY25 revenues at ₹33.8 billion, YoY growth of 1% and QoQ decline of 9%. Volume growth coupled with new product launches and favourable forex was offset by price erosion on a YoY basis. The sequential decline was largely on account of lower sales of certain products including Lenalidomide.
  
  9MFY25 revenues at ₹109.6 billion, YoY growth of 13%. The YoY growth was largely on account of increase in demand for our product portfolio, contribution from new product launches, partially offset by price erosion in few key products.

• During the quarter, we launched four new products in the U.S. A total of 11 products were launched during the nine months ended December 31, 2024.
• We filed three new Abbreviated New Drug Applications (ANDAs) with the USFDA during the nine months ended December 31, 2024. As of December 31, 2024, 79 generic filings were pending approval from the USFDA. These comprise of 75 ANDAs and four New Drug Applications (NDAs) filed under Section 505(b)(2) route of the US Federal Food, Drug, and Cosmetic Act. Of the 75 ANDAs, 44 are Paragraph IV applications, and we believe that 20 of these have the ‘First to File’ status.

Europe

• Q3FY25 revenues at ₹12.1 billion, YoY growth of 143% and QoQ growth of 110%. Q3FY25 revenues includes revenues from the recently acquired NRT portfolio. Underlying growth excluding NRT is 22% YoY and 5% QoQ.
  • NRT at ₹6.0 billion
  • Germany at ₹3.3 billion, YoY growth of 24% and QoQ growth of 3%
  • UK at ₹1.9 billion, YoY growth of 39% and QoQ growth of 16%.
  • Rest of Europe at ₹0.8 billion, YoY decline of 10% and QoQ decline of 8%

• 9MFY25 revenues at ₹23.1 billion, YoY growth of 51%. Underlying YoY growth excluding NRT is 12%.
  • NRT at ₹6.0 billion
  • Germany at ₹9.3 billion, YoY growth of 20%.
  • UK at ₹5.1 billion, YoY growth of 6%.
  • Rest of Europe at ₹2.6 billion, YoY decline of 2%

• The growth was primarily on account of revenues from the acquired NRT Portfolio, new product launches and momentum in the base business, partly offset by price erosion.
• During the quarter, we launched nine new products in the region, taking the year-to-date total to 29.

India

• Q3FY25 revenues at ₹13.5 billion, YoY growth of 14% and QoQ decline of 4%.
• 9MFY25 revenues at ₹40.7 billion, YoY growth of 16%.
  
  Growth was led by revenues from the in-licensed vaccine portfolio, new product launches as well as price increases, partially offset by lower volume pick-up in certain brands in Cardiac and Gastro-intestinal therapy areas.

• As per IQVIA, our IPM rank was maintained at 10. During the quarter, we launched six new brands in the country, taking the year-to-date total to 22.

Emerging Markets

• Q3FY25 revenues at ₹14.4 billion, YoY growth of 12% and flat QoQ. YoY growth is attributable to market share expansion as well as new product launches.

- Revenues from Russia at ₹7.0 billion, YoY growth of 19% and QoQ growth of 2%. YoY growth was due to higher volumes, price increase and new product launches, partially offset by adverse forex movement.

- Revenues from other Commonwealth of Independent States (CIS) countries and Romania at ₹2.4 billion, YoY growth of 4% and QoQ growth of 13%. YoY growth was due to higher prices and contribution from new product launches, partially offset by adverse forex movement. QoQ growth was primarily on account of higher base business volumes.

- Revenues from Rest of World (RoW) territories at ₹4.9 billion, YoY growth of 7% YoY and QoQ decline of 11%. YoY growth was primarily due to contribution from new product launches, partially offset by adverse forex movement. QoQ decline was largely due to decrease in base business volumes.

• 9MFY25 revenues at ₹40.8 billion, YoY growth of 12%. The growth is attributable to market share expansion and new product launches, partly offset by unfavorable forex.

- Revenues from Russia at ₹19.4 billion, YoY growth of 12%. The growth was largely on account of price increases in certain brands and improved volumes, partially offset by adverse forex.

- Revenues from other CIS countries and Romania at ₹6.5 billion, flat YoY.

- Revenues from RoW territories at ₹14.9 billion, YoY growth of 17%. The growth is largely due to higher base business volumes and new product launches, partially offset by price erosion.

During Q3FY25, we launched 20 new products across countries, with the year-to-date total to 59.

Pharmaceutical Services and Active Ingredients (PSAI)

• Q3FY25 revenues at ₹8.2 billion, YoY growth of 5% and QoQ decline of 2%. YoY Growth in PSAI business was due to increase in volumes, new launches and favourable forex, partially offset by adverse price variance. QoQ decline was primarily due to moderation in the growth of the services business.
• 9MFY25 revenues at ₹24.3 billion, with a growth of 13% YoY. The growth was mainly driven by market share expansion, growth in services business and revenues from new products.
  
  During the quarter, we filed 23 Drug Master Files (DMFs) globally, taking the year-to-date count to 59.

Income Statement Highlights:

Gross Margin

• Q3FY25 at 58.7% (GG: 61.3%, PSAI: 28.6%), a YoY increase of 20 basis points (bps) and a QoQ decline of 91 bps. The YoY increase was primarily on account of favourable product mix, manufacturing overhead leverage, partly offset by price erosion. On a sequential basis, the decline was primarily on account of unfavorable product mix.
  9MFY25 at 59.5% (GG: 63.0%, PSAI: 27.3%), a YoY increase by 91 bps YoY. The expansion in margin was on account of favourable product mix, cost optimisation, partially offset by price erosion.

Selling, General & Administrative (SG&A) Expenses

• Q3FY25 at ₹24.1 billion, YoY increase of 19% and QoQ increase of 5%.
  9MFY25 at ₹69.8 billion, YoY increase of 23%.
  
  The increase is largely on account of costs associated with the NRT business, higher investments in sales & marketing activities to strengthen our existing brands, new business initiatives, including scaling up of consumer health businesses and higher freight costs.

Research & Development (R&D) Expenses

• Q3FY25 at ₹6.7 billion. As % to Revenues – Q3FY25: 8.0% | Q3FY24: 7.7% | Q2FY25: 9.1%.
  9MFY25 at ₹20.1 billion. As % to Revenues – 9MFY25: 8.4% | 9MFY24: 7.7%.
  
  R&D investments are related to our ongoing development efforts across complex generics, peptides, biosimilars, as well as our novel oncology assets.

Net Finance Income

• Q3FY25 at ₹(0.02) billion compared to ₹1.0 billion in Q3FY24.
  The decrease was on account of higher foreign currency exchange loss as well as interest expense in comparison to interest income in the corresponding quarter of the previous year.
  9MFY25 at ₹2.4 billion as compared to ₹3.0 billion in 9MFY24.

Income Tax

• Q3FY25 at ₹4.7 billion. As % to PBT – Q3FY25: 25.1% | Q3FY24: 24.5% | Q2FY25: 30%.
  9MFY25: The ETR was 27.1% as compared to 23.7% in 9MFY24.
  
  The higher tax for the nine months ended December 31, 2024 is primarily on account of:

- the reversal of a previously recognized deferred tax asset on indexation of land;

- change in the mix of tax jurisdictions; and

- the recognition of a previously unrecognized deferred tax asset on operating tax losses, primarily pertaining to Dr. Reddy’s Laboratories SA, Switzerland, during the nine months ended December 31, 2023.

Profit before tax

• Q3FY25 at ₹18.7 billion, a YoY growth of 3% and a QoQ decline of 2%.
  As % to Revenues – Q3FY25: 22.4% | Q3FY24: 25.3% | Q2FY25: 23.9%.
  Profit before tax includes ₹1,240 Mn from the recently acquired NRT business.
  9MFY25 at ₹56.7 billion, a YoY growth of 2%.

Profit attributable to Equity Holders of Parent Company

• Q3FY25 at ₹14.1 billion, a YoY growth of 2% and a QoQ growth of 13%.
  As % to Revenues – Q3FY25: 16.9% | Q3FY24: 19.1% | Q2FY25: 15.7%.
  9MFY25 at ₹40.6 billion, a YoY decline of 5%. As % to Revenues – 9MFY25: 16.9% | 9MFY24: 20.5%.

Diluted Earnings per Share (EPS)

• Q3FY25 is ₹16.94. 9MFY25 is ₹48.68.
  The Earnings per share has been arrived at on the increased number of shares pursuant to the stock split of one fully paid-up equity share of Rupees five each into five fully paid-up equity share of Rupee one each.

Other Highlights:

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

• Q3FY25 at ₹23.0 billion, YoY growth of 9% and flat QoQ.
  As % to Revenues – Q3FY25: 27.5% | Q3FY24: 29.3% | Q2FY25: 28.4%.
• 9MFY25 at ₹67.4 billion, a YoY growth of 5%. As % to Revenues – 9MFY25: 28.0% | 9MFY24: 30.9%.

Others:

• Operating Working Capital : As on 31^st December 2024 at ₹127.8 billion.
• Capital Expenditure: Q3FY25 at ₹7.1 billion.
• Cash Flow: Q3FY25 at ₹(2.1) billion.
• Net Cash Surplus: As on 31^st December 2024 at ₹16.0 billion
• Net Debt to Equity: As on 31^st December 2024 is (0.05)
• ROCE: Q3FY25 at 27.8% (Annualized)

About key metrics and non-GAAP Financial Measures

This press release contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are adjusted to exclude or include amounts from the most directly comparable financial measure calculated and presented in accordance with IFRS.

The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Our non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.

We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.

For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please refer to "Reconciliation of GAAP to Non-GAAP Results" table in this press release.

All amounts in millions, except EPS

Computation of EBITDA

Refer page no. 3 & 4.

Earnings Call Details

The management of the Company will host an Earnings call to discuss the Company’s financial performance and answer any questions from the participants.

Date: January 23, 2025

Time: 19:30 pm IST | 09:00 am ET

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

Play Back: The play back will be available after the earnings call, till January 30^th, 2025. For play back dial in phone No: +91 22 7194 5757, and Playback Code is 40359#.

Transcript: Transcript of the Earnings call will be available on the Company’s website: www.drreddys.com

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.

For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2024 and quarterly financial statements filed in Form 6-K with the US SEC for the quarter ended June 30, 2024, September 30, 2024 and our other filings with US SEC. The company assumes no obligation to update any information contained herein.